CRHKY Financials 07/19/2014 11:06:35
CRHKY Financials 07/19/2014 11:06:35
China Resources Enterprise Ltd.
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research and Development
Sales, General and Admin.
Non-Recurring Items
Other
Operating Income
Income From Continuing Operations
Add'l Income/Expense Items
Earnings Before Interest and Tax
Interest Expense
Earnings Before Tax
Income Tax
Minority Interest
Equity Earnings Unconsolidated Subsidiary
Net Income Cont. Operations
Non Recurring Events
Discontinued Operations
Extraordinary Items
Effect of Accounting Changes
Other Items
Net Income
Preferred Stock and Other Adjustments
Net Income Applicable to Common Shareholders
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...
Continue Reading
The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...
Continue Reading
A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...
Continue Reading
Onodrim Industries' Bold Bid to Reshape European Security Right out of the gate, Onodrim Industries is thundering onto the scene with a hefty $300 million Series A round to flex its muscles across Europe's defence and industrial sectors. This ain't your run-of-the-mill startup story. This is about flexing hard-earned capital to snap up established players and inject a...
Continue Reading
Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...
Continue Reading
Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...
Continue Reading
Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...
Continue Reading
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
Top 5 Most Recently Viewed Articles
Foresight Group's Share Buyback Details Foresight Group Holdings Limited, known for its prowess in investment management, is actively engaged in a strategic share buyback initiative. This initiative underpins the Group's commitment to enhancing shareholder value while maintaining a strong balance sheet. In line with the buyback program introduced earlier this year, the...
Continue Reading
Douglas Elliman Introduces Elliman Capital for Home Financing In a significant development for luxury real estate, Douglas Elliman Real Estate has announced the launch of Elliman Capital, a pioneering in-house mortgage platform. This exciting new service aims to simplify the home financing experience for clients while catering to both traditional and non-traditional...
Continue Reading
Understanding Recent Market Dynamics In recent weeks, global markets have been experiencing heightened volatility, particularly in the technology sector. With various significant events unfolding—including new political leadership in Japan and shifts in economic data—investors are carefully analyzing these developments to navigate potential risks and opportunities....
Continue Reading
Hark Capital Closes $50 Million NAV Facility Hark Capital proudly announces the closing of a significant $50 million Net Asset Value (NAV) facility in partnership with Pharos IV-A, L.P. This middle-market private equity fund is dedicated to enhancing healthcare companies that prioritize improving patient care, expanding access to underserved communities, and lowering the...
Continue Reading
Kinder Morgan's Q4 Earnings Report Overview Kinder Morgan (NYSE: KMI) has recently made headlines following its earnings report for the fourth quarter. The company revealed its earnings details, shedding light on its financial health and performance metrics. Earnings Performance and Insights In the recent earnings announcement, Kinder Morgan reported earnings that fell...
Continue Reading